An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
electroCore, Inc. (Nasdaq: ECOR) will announce its first quarter financial results on May 8, 2024, after the market closes. The company, specializing in bioelectronic medicine and wellness, will hold a conference call to discuss the results and answer questions.
electroCore, Inc. (Nasdaq: ECOR) annuncerà i risultati finanziari del primo trimestre l'8 maggio 2024, dopo la chiusura del mercato. La società, specializzata in medicina bioelettronica e benessere, terrà una conferenza telefonica per discutere i risultati e rispondere alle domande.
electroCore, Inc. (Nasdaq: ECOR) anunciará sus resultados financieros del primer trimestre el 8 de mayo de 2024, después del cierre del mercado. La empresa, especializada en medicina bioelectrónica y bienestar, realizará una conferencia telefónica para discutir los resultados y responder preguntas.
electroCore, Inc.(Nasdaq: ECOR)는 2024년 5월 8일 시장 마감 후 1분기 재무 결과를 발표할 예정입니다. 생체전자 의학 및 웰니스를 전문으로 하는 이 회사는 결과에 대해 논의하고 질문에 답하기 위해 컨퍼런스 콜을 개최할 것입니다.
electroCore, Inc. (Nasdaq: ECOR) annoncera ses résultats financiers pour le premier trimestre le 8 mai 2024, après la fermeture du marché. L'entreprise, spécialisée en médecine bioélectronique et bien-être, tiendra une conférence téléphonique pour discuter des résultats et répondre aux questions.
electroCore, Inc. (Nasdaq: ECOR) wird seine Finanzergebnisse für das erste Quartal am 8. Mai 2024 nach Börsenschluss bekannt geben. Das Unternehmen, das auf bioelektronische Medizin und Wellness spezialisiert ist, wird eine Telefonkonferenz abhalten, um die Ergebnisse zu diskutieren und Fragen zu beantworten.
Positive
None.
Negative
None.
ROCKAWAY, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial results for the first quarter ended March 31, 2024, after the close of the market on Wednesday, May 8, 2024. Management will host a conference call and webcast at 4:30 PM EDT to discuss the financial results and answer questions.
About electroCore, Inc. electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving health through its non-invasive vagus nerve stimulation (“nVNS”) technology platform. Our focus is the commercialization of medical devices for the management and treatment of certain medical conditions and consumer product offerings utilizing nVNS to promote general wellbeing and human performance in the United States and select overseas markets.
When will electroCore announce its first quarter financial results for March 31, 2024?
electroCore will announce its first quarter financial results on Wednesday, May 8, 2024, after the market closes.
What is the stock symbol of electroCore?
electroCore's stock symbol is ECOR.
How can I participate in the conference call to discuss the financial results?
You can participate in the conference call by dialing 877-407-8835 (Domestic) or the international number provided, using the Conference ID: 13744118. Additionally, you can join the webcast on electroCore's Earnings Webcast.
electrocore is, a us based electroceutical healthcare company, which is developing a range of non-invasive vagus nerve stimulation (nvns) patient administered therapies for the treatment of multiple conditions in neurology, psychiatry, gastroenterology and other fields. initial focus is on primary headache (migraine and cluster headache), with trials continuing in epilepsy, gastric motility disorders, depression and anxiety. electrocore, which was founded in 2005, has more than 30 employees and full time consultants with offices in the us (head office), germany (german and european head office), uk, italy, australia, and canada.
